Stay updated on HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial

Sign up to get notified when there's something new on the HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:39:26.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the primary objective of a single arm phase 2 trial assessing the response rate of combined nivolumab and HD IL-2 in subjects with metastatic melanoma and renal cell carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:54.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying requirements such as the ability to provide informed consent, age, prior treatments, and specific health conditions. Previously, no information was provided under the Participation Criteria section.
    Difference
    41%
    Check dated 2024-05-22T21:34:07.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:35:27.000Z thumbnail image

Stay in the know with updates to HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial page.